Patients with one type of major histocompatibility complex class II combined immunodeficiency have mutations in a gene termed class II transactivator (CIITA), which coordinately controls the transcription of the three major human class II genes, HLA-DR, -DQ, and -DP. However, the experimentally derived B-lymphoblastoid cell line, clone 13, expresses high levels of HLADQ in the absence of HLA-DR and HLA-DP, despite its mapping by complementation analysis to this group. It was possible that one of the clone 13 CIITA alleles bore a mutation that allowed HLA-DQ, but not HLA-DR or -DP transcription. Alternatively, another factor, distinct from CIITA, might control HLA-DQ expression. We report here that ectopic expression of CIITA cDNAs derived by reverse transcriptase polymerase chain reaction from clone 13 do not restore expression of HLA-DQ in another CIITA-deficient cell line, RJ2.2.5. In addition, no CIITA protein is detectable in clone 13 nuclear extracts. In contrast, somatic cell fusion between clone 13 and RJ2.2.5 restored expression of the HLA-DQ haplotype encoded by the RJ2.2.5 DQB gene. Taken together, these data demonstrate the existence of an HLA-DQ isotype-specific trans-acting factor, which functions independently of CIITA.
Skip Nav Destination
Article navigation
2 June 1997
Article|
June 02 1997
An Isotype-specific Activator of Major Histocompatibility Complex (MHC) Class II Genes That Is Independent of Class II Transactivator
John Douhan, III,
John Douhan, III
From the *Harvard School of Public Health, Department of Cancer Biology, Boston, Massachusetts 02115; ‡Program in Immunology, Harvard Medical School, Boston, Massachusetts, 02115; §Division of Genetics, Children's Hospital and Department of Pathology, Beth Israel Hospital, Boston, Massachusetts, 02115; and the ‖Department of Medicine, Harvard Medical School, Boston, Massachusetts, 02115
Search for other works by this author on:
Rebecca Lieberson,
Rebecca Lieberson
From the *Harvard School of Public Health, Department of Cancer Biology, Boston, Massachusetts 02115; ‡Program in Immunology, Harvard Medical School, Boston, Massachusetts, 02115; §Division of Genetics, Children's Hospital and Department of Pathology, Beth Israel Hospital, Boston, Massachusetts, 02115; and the ‖Department of Medicine, Harvard Medical School, Boston, Massachusetts, 02115
Search for other works by this author on:
Joan H.M. Knoll,
Joan H.M. Knoll
From the *Harvard School of Public Health, Department of Cancer Biology, Boston, Massachusetts 02115; ‡Program in Immunology, Harvard Medical School, Boston, Massachusetts, 02115; §Division of Genetics, Children's Hospital and Department of Pathology, Beth Israel Hospital, Boston, Massachusetts, 02115; and the ‖Department of Medicine, Harvard Medical School, Boston, Massachusetts, 02115
Search for other works by this author on:
Hong Zhou,
Hong Zhou
From the *Harvard School of Public Health, Department of Cancer Biology, Boston, Massachusetts 02115; ‡Program in Immunology, Harvard Medical School, Boston, Massachusetts, 02115; §Division of Genetics, Children's Hospital and Department of Pathology, Beth Israel Hospital, Boston, Massachusetts, 02115; and the ‖Department of Medicine, Harvard Medical School, Boston, Massachusetts, 02115
Search for other works by this author on:
Laurie H. Glimcher
Laurie H. Glimcher
From the *Harvard School of Public Health, Department of Cancer Biology, Boston, Massachusetts 02115; ‡Program in Immunology, Harvard Medical School, Boston, Massachusetts, 02115; §Division of Genetics, Children's Hospital and Department of Pathology, Beth Israel Hospital, Boston, Massachusetts, 02115; and the ‖Department of Medicine, Harvard Medical School, Boston, Massachusetts, 02115
Search for other works by this author on:
John Douhan, III
From the *Harvard School of Public Health, Department of Cancer Biology, Boston, Massachusetts 02115; ‡Program in Immunology, Harvard Medical School, Boston, Massachusetts, 02115; §Division of Genetics, Children's Hospital and Department of Pathology, Beth Israel Hospital, Boston, Massachusetts, 02115; and the ‖Department of Medicine, Harvard Medical School, Boston, Massachusetts, 02115
Rebecca Lieberson
From the *Harvard School of Public Health, Department of Cancer Biology, Boston, Massachusetts 02115; ‡Program in Immunology, Harvard Medical School, Boston, Massachusetts, 02115; §Division of Genetics, Children's Hospital and Department of Pathology, Beth Israel Hospital, Boston, Massachusetts, 02115; and the ‖Department of Medicine, Harvard Medical School, Boston, Massachusetts, 02115
Joan H.M. Knoll
From the *Harvard School of Public Health, Department of Cancer Biology, Boston, Massachusetts 02115; ‡Program in Immunology, Harvard Medical School, Boston, Massachusetts, 02115; §Division of Genetics, Children's Hospital and Department of Pathology, Beth Israel Hospital, Boston, Massachusetts, 02115; and the ‖Department of Medicine, Harvard Medical School, Boston, Massachusetts, 02115
Hong Zhou
From the *Harvard School of Public Health, Department of Cancer Biology, Boston, Massachusetts 02115; ‡Program in Immunology, Harvard Medical School, Boston, Massachusetts, 02115; §Division of Genetics, Children's Hospital and Department of Pathology, Beth Israel Hospital, Boston, Massachusetts, 02115; and the ‖Department of Medicine, Harvard Medical School, Boston, Massachusetts, 02115
Laurie H. Glimcher
From the *Harvard School of Public Health, Department of Cancer Biology, Boston, Massachusetts 02115; ‡Program in Immunology, Harvard Medical School, Boston, Massachusetts, 02115; §Division of Genetics, Children's Hospital and Department of Pathology, Beth Israel Hospital, Boston, Massachusetts, 02115; and the ‖Department of Medicine, Harvard Medical School, Boston, Massachusetts, 02115
Address correspondence to Dr. Laurie H. Glimcher, Harvard School of Public Health, Department of Cancer Biology, 665 Huntington Avenue, Boston, Massachusetts, 02115.
1 Abbreviations used in this paper: B-LCL, B-lymphoblastoid cell line; CID, combined immunodeficiency; CIITA, class II transactivator; EMSA, electrophoretic mobility shift assays.
Received:
August 14 1996
Revision Received:
April 03 1997
Online ISSN: 1540-9538
Print ISSN: 0022-1007
1997
J Exp Med (1997) 185 (11): 1885–1895.
Article history
Received:
August 14 1996
Revision Received:
April 03 1997
Citation
John Douhan, Rebecca Lieberson, Joan H.M. Knoll, Hong Zhou, Laurie H. Glimcher; An Isotype-specific Activator of Major Histocompatibility Complex (MHC) Class II Genes That Is Independent of Class II Transactivator. J Exp Med 2 June 1997; 185 (11): 1885–1895. doi: https://doi.org/10.1084/jem.185.11.1885
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement